anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The rotator cuff is a system of tendons in the shoulder that stabilize the ball within the socket. These tendons frequently tear with age, which causes pain, weakness, and dysfunction in the shoulder. While these tears can be surgically repaired, they do not always heal. Our data suggest that deficiency of testosterone and estrogen can contribute to both tearing of the rotator cuff and failure of healing after rotator cuff repair. Testosterone can be converted into estrogen in the body through the aromatase enzyme, which is in both tendons and bones, as well as other tissues. Both testosterone and estrogen can improve bone quality. While testosterone is frequently prescribed for testosterone deficiency, when it is given your body no longer has the drive to make testosterone. So when the treatment is withdrawn testosterone levels can go very low until feedback mechanisms in the body motivate it to make more. As a result, testosterone is not usually given temporarily. For temporary treatment clomiphene avoids this issue. Clomiphene works at the feedback mechanisms within the body to trick the body into thinking testosterone and estrogen levels are low and thus to motivate it to make more testosterone and estrogen. However, clomiphene can only be given continuously to men, because women's estrogen levels regularly cycle up and down on a monthly basis and clomiphene interferes with this cycle. The purpose of this study is to determine whether clomiphene treatment decreases pain and improves function, increases tendon healing, and improves bone quality with rotator cuff repair in men. We hypothesize that clomiphene treatment will decrease pain and improve function, improve tendon healing, and improve bone quality with rotator cuff repair in men. This is a placebo-controlled study, so a control group of patients will received placebo pills, i.e. "sugar pills", instead of clomiphene. This is a randomized study, so patients enrolled in the study will be randomly assigned to the clomiphene group or the placebo group. This is a blinded study, so both the patients enrolled in the will not know whether they are in the clomiphene or the control group. This is a double-blinded study, so the doctors performing the surgeries and the study will not know whether each specific patient is in the clomiphene or the control group. Study participants will first start the clomiphene treatment one month before surgery and will continue the treatment for six months after surgery. Both before surgery and six months after surgery, study participants will fill out study questionnaires about shoulder pain and function. Both before surgery and six months after surgery, study participants will undergo an magnetic resonance imaging study to examine the rotator cuff tendons as well as the bone quality within the shoulder. The magnetic resonance imaging study after surgery is provided free to study participants. Study participants will be compensated for completing the study. These results are important because may lead to a better understanding of the problem, more effective treatment, and improved clinical outcomes for future patients.
A number of facial expressions are associated with pain in horses, however, the entire display of facial activities during orthopedic pain have yet to be described. The aim of the present study was to exhaustively map changes in facial activities in eight resting horses during a progression from sound to mild and moderate degree of orthopedic pain, induced by lipopolysaccharides (LPS) administered in the tarsocrural joint. Lameness progression and regression was measured by objective gait analysis during movement, and facial activities were described by EquiFACS in video sequences (n = 348, total length 892.5 min) of the horses obtained when resting in their box stalls. Predictive modeling identified 16 action units and action descriptors, related to ears, eyes, and lower face. Lower lip depressor (AU16), lips part (AU25), half blink (AU47), single ear forward (SEAD101) and single ear rotator (SEAD104) were selected as co-occurring significantly more in horses with pain than in horses without pain. The major change in co-occurring facial activities occurred in the transition from no pain to mild pain. In conclusion, resting horses with induced orthopedic pain showed a dynamic upper and lower facial repertoire and the relationship between level of pain intensity and facial activity appears complex.
The invention discloses a method for synthesizing O-quaternized vanillyl chitosan carbon residue particles based on an amphiphilic biological carbon material, and belongs to the technical field of biology. The synthesis method comprises the steps of preparing an amphiphilic biological carbon material by using beer yeast cells through a hydrothermal synthesis method, grafting chitosan by using the amphiphilic carbon material as a carrier through a covalent bonding method, and performing structural modification on chitosan carbon residue particles by using vanillin and glycidol trimethyl ammonium chloride as modified materials through a chemical method to obtain functionalized carbon residue particles. A series of characterization methods verify the successful covalent modification of chitosan, vanillin and glycidol trimethyl ammonium chloride. The functionalized carbon residue particles synthesized by the method have high dispersibility in polar and non-polar solvents while retaining the antibacterial property of the quaternized chitosan. The synthesis method has simple process and low cost. The synthetic product has low irritation, good biocompatibility, excellent antibacterial performance and good amphipathy.
Secreted frizzled related protein 5 (SFRP5) is a recognized cardioprotective protein with diminished expression in atrial fibrillation (AF). This study investigates SFRP5's function in AF-related cardiac fibrosis and cardiomyocyte apoptosis, exploring the underlying dysregulation causes. Utilizing C57BL/6 mice, mouse cardiac fibroblasts (CFs), and HC-1 mouse atrial myocyte cell line, AF models were induced by angiotensin Ⅱ (Ang Ⅱ). SFRP5 levels were consistently decreased in plasma samples from clinical patients, modeled mice, and CF culture supernatants. Treatment with recombinant SFRP5 restored its levels, mitigating Ang Ⅱ-induced AF in mice and ameliorating atrial tissue fibrosis and oxidative stress. In vitro, SFRP5 recombinant protein suppressed CF activation and fibrosis-related markers. The study identified Sp1 transcription factor (SP1) binding to the SFRP5 promoter, causing transcriptional repression. SP1 knockdown reinstated SFRP5 levels in mice and CFs, thus suppressing fibrosis. Additionally, SP1 knockdown attenuated Ang Ⅱ-induced apoptosis in HC-1 cells, but this effect was counteracted by concurrent SFRP5 knockdown. In conclusion, this investigation underscores that SP1 mediates SFRP5 loss during AF by transcriptional repression, contributing to fibrosis and myocyte apoptosis. These findings illuminate potential therapeutic interventions targeting the SFRP5-SP1 axis in AF-related cardiac complications.
Drug-eluting stents (DES) have drastically changed the landscape of percutaneous coronary intervention (PCI), with significant reductions in the angiographic restenosis rate and need for repeated revascularization. However, several studies showed that DES is associated with a higher incidence of in-stent thrombosis compared with bare metal stents. Therefore, the latest guideline for antiplatelet therapy after PCI with DES suggests that the dual antiplatelet therapy (aspirin plus clopidogrel) be administered for at least 12 months.But is it enough for high-risk patients? Some studies showed that as many as 50% of the patients who received PCI did not react positively to aspirin or clopidogrel.Furthermore, there is increased platelet activity in acute coronary syndrome, especially in acute myocardial infarction (AMI). compared with aspirin or clopidogrel.A recent study suggested that cilostazol could ameliorate platelet responsiveness to clopidogrel in patients who underwent primary PCI. Furthermore, some other studies showed that the administration of cilostazol after PCI could significantly lower the incidence of in-stent restenosis. Therefore, the present study is designed to evaluate the safety and efficacy of additional administration of cilostazol with aspirin and clopidogrel in a real-world cardiology practice among patients presenting with AMI who received primary PCI with DES.
The present invention provides an oral dosage form comprising a first composition and a second composition. The first composition comprises an effective amount of a therapeutic agent and the second composition comprises an effective amount of an adverse-effect agent. The adverse-effect agent is covered with a coating that is substantially insoluble in the gastrointestinal tract. In one embodiment, the adverse-effect agent is coated with an outer base-soluble layer and an inner acid-soluble layer. The therapeutic agent can be uncoated or can be coated with a coating having an outer acid-soluble layer and an inner base-soluble layer. The dosage form discourages administration of the therapeutic agent by other than oral administration.
The participants of the Control Group receives treatment as usual, which consists of a regular follow-up program with neurodevelopmental assessment at term age, 3 months corrected age, 12 months corrected age, 24 months corrected age and 66 months corrected age. Compared to children not participating in the study, the control group will receive an extended follow-up program, with assessment and questionnaires at term age, 3 months corrected age, 12 months corrected age, 24 months corrected age and 36 months corrected age. Participants in the control group will be referred to specialized care when needed.
PURPOSE: Fermented red ginseng with enhanced content of ginsenoside Rg3, Rg5, and Rk1 is provided to improve memory. CONSTITUTION: A method for preparing fermented red ginseng comprises: a step of adding red ginseng to 15-25 times weight of purified water and extracting at 115-125 deg. C for 1-3 hours to prepared an extract; a step of cooling the extract at 30-40 deg. C and inoculating 2-5% of Lactobacillus fermentum JS(LBF,KCCM-10499) to the extract; a step of fermenting at 12-120 hours and preparing a fermentation; and a step of performing thermal treatment of the fermentation at 115-125 deg. C for 10-30 minutes. The method further comprises a step of adding purified water to the red ginseng and treating the red ginseng by an electric field at 5-20kv for 30 seconds to 5 minutes.
A method and system for providing a form record and for processing the same. For example, a medical record form in a clinical or hospital environment is provided based on user input and is processed upon the user's filling in of the form. In some aspects, a user indicates by way of a user interface a type of patient complaint and selects a type of medical record form that is to be used in conjunction with examining the patient. The system guides the user and accepts the user's inputs and provides a suitable medical record form from a plurality of form types. The selected form is printed, and used by the medical staff in the examination of the patient. The filled form is then returned to a processing station for scanning, where information in the filled form may be extracted and where the filled form may be added to a patient medical record or archive, or shared with another person or organization.
PURPOSE: Sarcopenia is a condition defined as loss of muscle mass and strength, associated with poor functional performance and disability. Sarcopenia can be exacerbated or worsened in presence of inflammation, sedentary lifestyle and cytokine imbalance, thus it frequently occurs in people affected by rheumatic diseases. This systematic literature review aims to explore the association between sarcopenia and spondyloarthritis (SpA) and its most frequent manifestation, i.e. ankylosing spondylitis (AS).
METHODS: The Scopus, PubMed, and Web of Science databases were searched for articles on muscle mass, muscle strength and axial SpA, from any date to November 2023. Only studies written in English were considered. The methodological quality of the studies included in the review was evaluated using the Newcastle-Ottawa Scales for observational studies and for case-control studies.
RESULTS: 190 papers were retrieved from the searches, 14 of which met the inclusion criteria. Rather than diagnosis of sarcopenia, pre-sarcopenia or probable sarcopenia were frequent in people with AS, with a great reduction especially of muscle strength. The pre-sarcopenia status appears to be related to high AS disease activity, suggesting that chronic inflammation resulting in pain, less movement and decreased physical activity could play a role in the muscle heath of AS patients.
CONCLUSIONS: Our review confirms the existence of an association between AS and loss of muscle strength-likely sarcopenia-already at a young age. Preventive and early strategies should be adopted to ensure successful aging for individuals with AS.
The milk food additive in the form of chewing or sucking tablets contains from 30 to 60 wt. % lactic acid product. It includes wholesome or skimmed milk fermented with selected strains of Lactobacillus delbrueckii subsp. Bulgaricus and containing viable lactic acid microorganisms over 1,000,000/1 g product, pectine and from 1.5 to 3.5 wt. % vitamin complex selected from vitamin A, vitamin C, Vitamin E, vitamins B1, B2, B12, niacin, calcium pantoneonate, folic acid, each one in a quantity within the pharmacological boundaries, optionally also mineral salts, as well as auxiliary substances such as calcium phosphate, aspargine, citric acid, dextrose, aromatizers. The product is suitable for organisms, for example, of older people who have reduced ability of assimilating natural milk. It is recommended to be included in the diet in cases of grave allergic and toxicoallergic diseases, in postoperative convalescence, for the normalization of intestinal peristalsis, in kidney, liver and goal bladder diseases, in need for immunostimulation effect and prophylactics of working in a contaminated environment, in mental and physical fatigue, as well for sportsmen and sportswomen. 1 claim
Patients treated with levodopa, a component of CREXONT, have reported falling asleep while engaged in activities of daily living, including the operation of motor vehicles, which sometimes resulted in accidents. Although many of these patients reported somnolence while on levodopa, some perceived that they had no warning signs, such as excessive drowsiness, and believed that they were alert immediately prior to the event (sleep attack). Some of these events have been reported more than 1 year after initiation of treatment.

Falling asleep while engaged in activities of daily living usually occurs in patients experiencing preexisting somnolence, although patients may not give such a history. For this reason, prescribers should reassess for drowsiness or sleepiness in CREXONT-treated patients, especially since some of the events occur well after the start of treatment. Prescribers should also be aware that patients may not acknowledge drowsiness or sleepiness until directly questioned about drowsiness or sleepiness during specific activities.

Before initiating treatment with CREXONT, advise patients of the potential to develop drowsiness and specifically ask about factors that may increase the risk for somnolence with CREXONT, such as concomitant sedating medications or the presence of a sleep disorder. Consider discontinuing CREXONT in patients who report significant daytime sleepiness or episodes of falling asleep during activities that require active participation (e.g., conversations, eating, etc.).

If a decision is made to continue CREXONT, patients should be advised not to drive and to avoid other potentially dangerous activities that might result in harm if the patients become somnolent. There is insufficient information to establish that dose reduction will eliminate episodes of falling asleep while engaged in activities of daily living.
PURPOSE:To obtain the title cosmetic base capable promoting intradermal blood circulation without causing offensive irritation on the skin, leading to prevention of skin roughness or dryness by incorporating the original cosmetic base with infrared-radiative ceramic powder. CONSTITUTION:The objective skin cosmetic base can be obtained by incorporating (A) the original cosmetic base such as massage cream, humectant cream or pack with (B) pref. 0.1-30 (esp. 2-15)wt.%, based on the component A, of infrared-radiative ceramic powder pref. 0.1-20mum in average size (e.g. oxide such as zirconia, titanium dioxide, alumina or silica, mixture thereof, black colored mixture prepared by further adding oxide(s) of manganese, iron, cobalt, etc., to the above mixture). The present cosmetic base is such that the infrared rays emitted from said powder are penetrated into the depths of the body through the skin and internally warm the body to dilate the fine blood vessels and improve blood circulation as well as to stimulate metabolism, leading to making the skin humectant and smooth.
Systems and methods for detecting worsening cardiac conditions such as worsening heart failure events are described. A system may include sensor circuits to sense physiological signals and signal processors to generate from the physiological signals first and second signal metrics. The system may include a risk stratifier circuit to produce a cardiac risk indication. The system may use at least the first signal metric to generate a primary detection indication, and use at least the second signal metric and the risk indication to generate a secondary detection indication. The risk indication may be used to modulate the second signal metric. A detector circuit may detect the worsening cardiac event using the primary and secondary detection indications.
Provided is a  mycobacterium  bactericide. The  mycobacterium  bactericide includes chlorous acid water. The free chlorine concentration of the chlorous acid water (as Cl) may be 50 ppm or more. A biofilm may be formed with the  mycobacterium . The  mycobacterium  may be  Mycobacterium intracellulare, Mycobacterium avium, Mycolicibacterium fortuitum  subsp.  fortuitum, Mycobacterium runyonii, Mycobacterium abscessus, Mycobacterium kansasii, M. avium  subsp.  paratuberculosis , or  Mycobacterium ulcerans . A medicine containing chlorous acid water is provided for preventing and/or treating MAC lung disease.
This group includes acute myocardial infarction (ST segment elevation and non ST segment elevation) and old myocardial infarction. The diagnostic basis of acute myocardial infarction: cardiac biomarkers (cardiac troponin and / or myocardial enzymes) increased or decreased, at least once the value exceeded the upper limit of normal, and there was the following evidence of myocardial ischemia: (1) clinical symptoms of myocardial ischemia（ 2) New changes of myocardial ischemia appeared in ECG, i.e. new ST segment changes or left bundle branch block（ 3) Pathological Q wave appeared in ECG（ 4) Imaging evidence showed new loss of myocardial viability or regional wall motion abnormalities. Diagnosis of old myocardial infarction: the patient provided a history of previous myocardial infarction and confirmed as old myocardial infarction by the third or First Hospital of Peking University.
This patent disclosure provides various embodiments of combining multiple modalities of non-text surgical data in forms of videos, images, and audios in a meaningful manner so that the combined data can be used to perform comprehensive data analytics for a surgical procedure. In some embodiments, the disclosed system can begin by receiving two or more modalities of surgical data during the surgical procedure. The system then time-synchronizes the two or more modalities of surgical data to generate two or more modalities of time-synchronized surgical data. Next, the system converts each modality of the time-synchronized surgical data into a corresponding array of values of a common format. The system then combines the two or more arrays of values to generate a combined set of values. The system subsequently performs comprehensive data analytics on the combined set of values to generate a surgical decision for the surgical procedure.
<P>PROBLEM TO BE SOLVED: To provide new polynucleotides encoding immunogenic HIV polypeptides.  <P>SOLUTION: New polynucleotides encoding immunogenic HIV polypeptides are provided. Use of the polynucleotides in applications including immunization, production of packaging cell lines, and production of HIV polypeptides is also provided. Polynucleotides encoding antigenic HIV polypeptides are provided, as is use of these polynucleotides and polypeptide products therefrom (including formulations of immunogenic compositions and use thereof). In specific embodiments, synthetic polynucleotides and/or expression cassettes, encoding HIV polypeptides, are provided.  <P>COPYRIGHT: (C)2010,JPO&INPIT
The present invention relates to a plaster for relieving cardiac spasm and a preparation method thereof. The traditional Chinese medicinal materials of Chinese asafetida, ginseng, astragalus root, nutgrass flatsedge, frankincense and myrrh are proportionally fried in vegetable oil for extracting effective components. After dregs are filtered, the vegetable oil is decocted until the vegetable oil forms beads when the vegetable oil is dropped. The vegetable oil and yellow lead are synthesized into the form of the plaster. When the plaster is cooled to a certain temperature, fine powder ground by pipe fish, sea horse and Chinese eaglewood is added and uniformly mixed. The mixture is immediately poured into cold water for clearing away heat and toxic materials. The plaster is spread on lining materials when the plaster is kept at a temperature of 50 DEG C to 80 DEG C. One dosage comprises three pieces, and the pieces are applied on the acupoints of Chihai, Shihmen, Guanyuan and Tsusanli on a left foot and a right foot. The plaster for relieving cardiac spasm mainly cures oesophagus cancer and cardia cancer. The plaster has the advantages of rapid and obvious effect taking, and safe and convenient use. The plaster is easily accepted by patients without toxic or side effect, and the total effective rate reaches 96%.
The invention discloses a low-toxicity high-stability antibacterial peptide synthesized based on cyclic lipopeptides Brivicidine and application thereof. The low-toxicity high-stability antibacterial peptide comprises a cyclic antibacterial peptide and a linear antibacterial peptide, wherein the cyclic antibacterial peptide is obtained by changing the positive charge type or the positive charge quantity of a natural cyclic lipopeptide Brevicidine, and then the linear antibacterial peptide is obtained by replacing N-terminal fatty acid and opening C-terminal of the cyclic antibacterial peptide with the positive charge quantity changed. Antibacterial activity experiments show that the synthesized cyclic antibacterial peptide has antibacterial activity on gram-negative bacteria, and the linear antibacterial peptide has broad-spectrum antibacterial activity on gram-negative bacteria and gram-positive bacteria. The hemolytic activity experiment shows that the antibacterial peptide with low toxicity and high stability has higher in-vitro safety. Salt ion stability experiments show that the antibacterial peptide with low toxicity and high stability has higher stability. Therefore, the low-toxicity high-stability antibacterial peptide has good application prospect in preparing clinical antibacterial medicines.